UnitedHealth Group shares climbed 7.3% over the past week after retail investor sentiment on Reddit and X swung from extreme negativity to a neutral posture. Sentiment scores rose from a low of 18 in November to a peak of 82 in December before settling at 42 out of 100 by late January. During that period, the stock stabilized around the mid‐$350s after having dropped sharply from its 52‐week high following the December 2024 shooting of UnitedHealthcare CEO Brian Thompson. Volume on social platforms fell 25%, but the tone shifted decisively, with r/options posts on deep in‐the‐money LEAPS driving sustained bullish commentary despite a temporary $310 low on the stock.

The Federal Trade Commission has issued a 14‐day suspension of its administrative case against UnitedHealth’s OptumRx unit, delaying the evidentiary hearing to July 1 and pushing back all discovery and filing deadlines. The original complaint, filed in September 2024, accuses OptumRx and other pharmacy benefit managers of unfair practices that inflated insulin list prices. The stay covers discovery, motion briefings and oral arguments, now rescheduled to February 5. Observers interpret the pause as a sign that settlement negotiations may be progressing, following a January report citing massive markups on specialty generics and political calls for PBM reform.